Japan's biggest drugmaker, Takeda Pharmaceutical, could acquire a company to help it enter the generic drug business in emerging markets, with a particular focus on South America, its president said on Monday.

Yasuchika Hasegawa, speaking after a speech on Japanese corporate management practices, also said the company was not interested in entering the generic business in Japan.

When asked what emerging markets Takeda might target, Hasegawa said the company was focused on South America.

He did not elaborate on potential targets.

(Reporting by Nathan Layne; Editing by Edwina Gibbs)